Hematología Oncológica y Trasplante

Averbuch D., Tridello G., Hoek J., Mikulska M., Pabst T., Yanez San Segundo L., Akan H., Ozcelik T., Donnini I., Klyasova G., Botelho de Sousa A., Zuckerman T., Tecchio C., de la Camara R., Aki S.Z., Ljungman P., Gulbas Z., Nicolas-Virelizier E., Calore E., Perruccio K., Ram R., Annaloro C., Martino R., Avni B., Shaw P.J., Jungova A., Codeluppi K., O'Brien T., Waszczuk-Gajda A., Batlle M., Pouli A., Lueck C., Gil L., Iacobelli S., Styczynski J., Engelhard D., Cesaro S. (2020) Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. J INFECTION, 81 (6), 882-894.

IF: 6,0720

Baron F., Labopin M., Ruggeri A., Sierra J., Robinson S., Labussiere-Wallet H., Potter M., Ribera J.-M., Deconinck E., Rambaldi A., Rohrlich P.-S., de Revel T., Gluckman E., Nagler A., Mohty M. (2020) Impact of detectable measurable residual disease on umbilical cord blood transplantation. AM J HEMATOL, 95 (9), 1057-1065.

IF: 10,0470

Bastos-Oreiro M., Muntanola A., Panizo C., Gonzalez-Barca E., de Villambrosia S.G., Cordoba R., Lopez J.L.B., Gonzalez-Sierra P., Terol M.J., Gutierrez A., Grande C., Ramirez M.J., Iserte L., Perez E., Navarro B., Gomez P., Salar A., Luzardo H., Lopez A., Del Campo R., Garcia-Belmonte D., Vida M.J., Infante M., Queizan-Hernandez J.A., Novelli S., Moreno M., Penarrubia M., Gomez J., Domingo A., Donato E., Viguria M.C., Lopez F., Rodriguez M.J., Pardal E., Noriega V., Andreu R., Penalver J., Martin A., Caballero D., Lopez-Guillermo A. (2020) RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. ANN HEMATOL, 99 (4), 799-808.

IF: 3,6730

Bataller A., Onate G., Diaz-Beya M., Guijarro F., Garrido A., Vives S., Tormo M., Arnan M., Salamero O., Sampol A., Coll R., Vall-Llovera F., Oliver-Caldes A., Lopez-Guerra M., Pratcorona M., Zamora L., Villamon E., Roue G., Blanco A., Nomdedeu J.F., Colomer D., Brunet S., Sierra J., Esteve J. (2020) Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. BRIT J HAEMATOL, 191 (1), 52-61.

IF: 6,9980

Bejanyan N., Zhang M., Bo-Subait K., Brunstein C., Wang H., Warlick E.D., Giralt S., Nishihori T., Martino R., Passweg J., Dias A., Copelan E., Hale G., Gale R.P., Solh M., Kharfan-Dabaja M.A., Diaz M.A., Ganguly S., Gore S., Verdonck L.F., Hossain N.M., Kekre N., Savani B., Byrne M., Kanakry C., Cairo M.S., Ciurea S., Schouten H.C., Bredeson C., Munker R., Lazarus H., Cahn J.-Y., van Der Poel M., Rizzieri D., Yared J.A., Freytes C., Cerny J., Aljurf M., Palmisiano N.D., Pawarode A., Bacher V.U., Grunwald M.R., Nathan S., Wirk B., Hildebrandt G.C., Seo S., Olsson R.F., George B., de Lima M., Hourigan C.S., Sandmaier B.M., Litzow M., Kebriaei P., Saber W., Weisdorf D. (2020) Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. BIOL BLOOD MARROW TR, (), -.

IF: 5,7420

Bento L., Diaz-Lopez A., Barranco G., Martin-Moreno A.M., Baile M., Martin A., Sancho J.M., Garcia O., Rodriguez M., Sanchez-Pina J.M., Novelli S., Salar A., Bastos M., Rodriguez-Salazar M.J., Gonzalez de Villambrosia S., Cordoba R., Garcia-Recio M., Martinez-Serra J., del Campo R., Luzardo H., Garcia D., Hong A., Abrisqueta P., Sastre-Serra J., Roca P., Rodriguez J., Gutierrez A. (2020) New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). BRIT J HAEMATOL, 188 (6), 888-897.

IF: 6,9980

Boque C., Abad M.R., Agustin M.J., Garcia-Goni M., Moreno C., Gabas-Rivera C., Granados E., Castro-Gomez A., Pardo C., Lizan L. (2020) Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study. J GERIATR ONCOL, 11 (1), 24-30.

IF: 3,5990

Burger J.A., Barr P.M., Robak T., Owen C., Ghia P., Tedeschi A., Bairey O., Hillmen P., Coutre S.E., Devereux S., Grosicki S., McCarthy H., Simpson D., Offner F., Moreno C., Dai S., Lal I., Dean J.P., Kipps T.J. (2020) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. LEUKEMIA, 34 (3), 787-798.

IF: 11,5280

Bussaglia E., Pratcorona M., Carricondo M., Sansegundo L., Rubio M.A., Monter A., Brell A., Badell I., Esteve J., Arnan M., Talarn C., Tormo M., Garcia A., Vall-Llovera F., Ortin X., Pedro C., Bargay J., Brunet S., Sierra J., Nomdedeu J. (2020) Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies). ANN HEMATOL, 99 (4), 765-772.

IF: 3,6730

Dandoy C.E., Kim S., Chen M., Ahn K.W., Ardura M.I., Brown V., Chhabra S., Diaz M.A., Dvorak C., Farhadfar N., Flagg A., Ganguly S., Hale G.A., Hashmi S.K., Hematti P., Martino R., Nishihori T., Nusrat R., Olsson R.F., Rotz S.J., Sung A.D., Perales M.-A., Lindemans C.A., Komanduri K.V., Riches M.L. (2020) Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplant. JAMA NETW OPEN, 3 (1), e1918668-.

IF: 8,4830

Davids M.S., Kuss B.J., Hillmen P., Montillo M., Moreno C., Essell J., Lamanna N., Nagy Z., Tam C.S., Stilgenbauer S., Ghia P., Delgado J., Lustgarten S., Weaver D.T., Youssoufian H., Jager U. (2020) Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. CLIN CANCER RES, 26 (9), 2096-2103.

IF: 12,5310

Diaz-Beya M., Labopin M., Maertens J., Alijurf M., Passweg J., Dietrich B., Schouten H., Socie G., Schaap N., Schwerdtfeger R., Volin L., Michallet M., Polge E., Sierra J., Mohty M., Esteve J., Nagler A. (2020) Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission. BRIT J HAEMATOL, 189 (5), 920-925.

IF: 6,9980

Diaz-Santa J., Rodriguez-Romanos R., Osca G., Pratcorona M., Garrido A., Coll R., Moret C., Escoda L., Tormo M., Heras I., Arnan M., Vives S., Salamero O., Lloveras N., Bargay J., Sampol A., Cruz D., Garcia A., Quinones T., Esteve J., Sierra J., Gallardo D. (2020) UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. LEUKEMIA, 34 (11), 2925-2933.

IF: 11,5280

Dohner K., Thiede C., Jahn N., Panina E., Gambietz A., Larson R.A., Prior T.W., Marcucci G., Jones D., Krauter J., Heuser M., Voso M.T., Ottone T., Nomdedeu J.F., Mandrekar S.J., Klisovic R.B., Wei A.H., Sierra J., Sanz M.A., Brandwein J.M., de Witte T., Jansen J.H., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori S., Gathmann I., Benner A., Pallaud C., Stone R.M., Dohner H., Bloomfield C.D. (2020) Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. BLOOD, 135 (5), 371-380.

IF: 22,1130

Escamilla Gomez V., Garcia-Gutierrez V., Lopez Corral L., Garcia Cadenas I., Perez Martinez A., Marquez Malaver F.J., Caballero-Velazquez T., Gonzalez Sierra P.A., Viguria Alegria M.C., Parra Salinas I.M., Calderon Cabrera C., Gonzalez Vicent M., Rodriguez Torres N., Parody Porras R., Ferra Coll C., Orti G., Valcarcel Ferreiras D., De la Camara LLanza R., Moles P., Velazquez-Kennedy K., Joao Mende M., Caballero Barrigon D., Perez E., Martino Bofarull R., Saavedra Gerosa S., Sierra J., Poch M., Zudaire Ripa M.T., Diaz Perez M.A., Molina Angulo B., Sanchez Ortega I., Sanz Caballer J., Montoro Gomez J., Espigado Tocino I., Perez-Simon J.A. (2020) Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. BONE MARROW TRANSPL, 55 (3), 641-648.

IF: 5,4830

Esquirol A., Querol S., Garcia-Cadenas I., Novelli S., Garrido A., Saavedra S., Moreno C., Granell M., Caballero A., Brunet S., Briones J., Martino R., Sierra J. (2020) When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). ANN HEMATOL, 99 (1), 157-165.

IF: 3,6730

Falgas A., Pallares V., Serna N., Sanchez-Garcia L., Sierra J., Gallardo A., Alba-Castellon L., Alamo P., Unzueta U., Villaverde A., Vazquez E., Mangues R., Casanova I. (2020) Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. THERANOSTICS, 10 (12), 5169-5180.

IF: 11,5560

Falgas A., Pallares V., Unzueta U., Cespedes M.V., Arroyo-Solera I., Moreno M.J., Gallardo A., Mangues M.A., Sierra J., Villaverde A., Vazquez E., Mangues R., Casanova I. (2020) A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. HAEMATOLOGICA, 105 (3), 741-753.

IF: 9,9410

Fox M.L., Garcia-Cadenas I., Perez A.M., Villacampa G., Pinana J.L., Orti G., Montoro J., Roldan E., Bosch Vilaseca A., Martino R., Salamero O., Saavedra S., Hernandez-Boluda J.C., Esquirol A., Sierra J., Sanz J., Solano C., Bosch F., Barba P., Valcarcel D. (2020) Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. LEUKEMIA LYMPHOMA, (), 1823-1832.

IF: 3,2800

Garcia-Cadenas I., Awol R., Esquirol A., Saavedra S., Bosch-Vilaseca A., Novelli S., Garrido A., Lopez J., Granell M., Moreno C., Briones J., Brunet S., Sierra J., Martino R. (2020) Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature. BONE MARROW TRANSPL, 55 (6), 1041-1049.

IF: 5,4830

Gascon y Marin I.G., Munoz-Novas C., Figueroa I., Hernandez-Sanchez M., Rodriguez-Vicente A.-E., Quijada-Alamo M., Perez-Carretero C., Moreno C., Collado R., Espinet B., Puiggros A., Heras N.D.L., Bosch F., Hernandez J.-A. (2020) Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. CL LYMPH MYELOM LEUK, 20 (8), 548-555.e4.

IF: 3,2310

Gonzalez-Barca E., Boumendil A., Blaise D., Trneny M., Masszi T., Finel H., Michieli M.G., Bittenbring J.T., Gritti G., Snowden J.A., Bishton M., Bruno B., de Villambrosia S.G., Janikova A., Leleu X., Anagnostopoulos A., Poire X., Crysandt M., Ozkurt Z.N., Vandenberghe E., Itala-Remes M., Cahn J.Y., Jantunen E., Schroyens W., Maertens J., Esquirol A., Dreger P., Montoto S., Sureda A. (2020) Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPL, 55 (2), 393-399.

IF: 5,4830

Gutierrez A., Bento L., Diaz-Lopez A., Barranco G., Garcia-Recio M., Lopez-Guillermo A., Dlouhy I., Rovira J., Rodriguez M., Sanchez Pina J.M., Baile M., Martin A., Novelli S., Sancho J.-M., Garcia O., Salar A., Bastos-Oreiro M., Rodriguez-Salazar M.J., Fernandez R., de la Cruz F., Queizan J.A., Gonzalez de Villambrosia S., Cordoba R., Lopez A., Luzardo H., Garcia D., Sastre-Serra J., Garcia J.F., Montalban C., Cabanillas F., Rodriguez J. (2020) Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. EUR J HAEMATOL, 104 (5), 400-408.

IF: 2,9970

Hernandez-Boluda J.-C., Pereira A., Alvarez-Larran A., Martin A.-A., Benzaquen A., Aguirre L., Mora E., Gonzalez P., Mora J., Dorado N., Sampol A., Garcia-Gutierrez V., Lopez-Godino O., Fox M.-L., Reguera J.L., Perez-Encinas M., Pascual M.-J., Xicoy B., Parody R., Gonzalez-Pinedo L., Espanol I., Avendano A., Correa J.-G., Vallejo C., Jurado M., Garcia-Cadenas I., Osorio S., Duran M.-A., Sanchez-Guijo F., Cervantes F., Pinana J.-L. (2020) Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. BIOL BLOOD MARROW TR, 26 (12), 2237-2244.

IF: 5,7420

Im A., Rashidi A., Wang T., Hemmer M., MacMillan M.L., Pidala J., Jagasia M., Pavletic S., Majhail N.S., Weisdorf D., Abdel-Azim H., Agrawal V., Al-Homsi A.S., Aljurf M., Askar M., Auletta J.J., Bashey A., Beitinjaneh A., Bhatt V.R., Byrne M., Cahn J.-Y., Cairo M., Castillo P., Cerny J., Chhabra S., Choe H., Ciurea S., Daly A., Perez M.A.D., Farhadfar N., Gadalla S.M., Gale R., Ganguly S., Gergis U., Hanna R., Hematti P., Herzig R., Hildebrandt G.C., Lad D.P., Lee C., Lehmann L., Lekakis L., Kamble R.T., Kharfan-Dabaja M.A., Khandelwal P., Martino R., Murthy H.S., Nishihori T., O'Brien T.A., Olsson R.F., Patel S.S., Perales M.-A., Prestidge T., Qayed M., Romee R., Schoemans H., Seo S., Sharma A., Solh M., Strair R., Teshima T., Urbano-Ispizua A., Van der Poel M., Vij R., Wagner J.L., William B., Wirk B., Yared J.A., Spellman S.R., Arora M., Hamilton B.K. (2020) Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. BIOL BLOOD MARROW TR, 26 (8), 1459-1468.

IF: 5,7420

Kanda J., Hayashi H., Ruggeri A., Kimura F., Volt F., Takahashi S., Labopin M., Kako S., Tozatto-Maio K., Yano S., Sanz G., Uchida N., Van Lint M.T., Kato S., Mohty M., Forcade E., Kanamori H., Sierra J., Ohno Y., Saccardi R., Fukuda T., Ichinohe T., Takanashi M., Rocha V., Okamoto S., Nagler A., Atsuta Y., Gluckman E. (2020) Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. LEUKEMIA, 34 (1), 128-137.

IF: 11,5280

Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Adès L, Montesinos P. Outcome of older (<70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. (2020) LEUKEMIA Sep;34(9):2333-2341. doi: 10.1038/s41375-020-0758-4. PMID: 32076120.

IF: 11,5280

Martino R., Garrido A., Santaliestra M., Garcia-Cadenas I., Novelli S., Saavedra S.D., Esquirol A., Granell M., Briones J., Moreno C., Brunet S., Gimenez A., Hidalgo A., Sanchez F., Sierra J. (2020) Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002–2018 Empirical/Pre-emptive Approach. MYCOPATHOLOGIA, 185 (4), 639-652.

IF: 2,5740

Mehta R.S., Holtan S.G., Wang T., Hemmer M.T., Spellman S.R., Arora M., Couriel D.R., Alousi A.M., Pidala J., Abdel-Azim H., Agrawal V., Ahmed I., Al-Homsi A.S., Aljurf M., Antin J.H., Askar M., Auletta J.J., Bhatt V.R., Chee L., Chhabra S., Daly A., DeFilipp Z., Gajewski J., Gale R.P., Gergis U., Hematti P., Hildebrandt G.C., Hogan W.J., Inamoto Y., Martino R., Majhail N.S., Marks D.I., Nishihori T., Olsson R.F., Pawarode A., Diaz M.A., Prestidge T., Rangarajan H.G., Ringden O., Saad A., Savani B.N., Schoemans H., Seo S., Schultz K.R., Solh M., Spitzer T., Storek J., Teshima T., Verdonck L.F., Wirk B., Yared J.A., Cahn J.-Y., Weisdorf D.J. (2020) Composite GRFS and CRFS Outcomes after Adult Alternative Donor HCT. J CLIN ONCOL, 38 (18), 2062-2076.

IF: 44,5440

Montesinos P., Gil A., Sierra J., Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs Estado actual de la leucemia mieloide aguda en España: Resultados de un estudio Delphi sobre su epidemiología, manejo de la enfermedad y necesidades clínicas no cubiertas (2020) MED CLIN-BARCELONA.

IF: 1,7250

Mora A., Bosch R., Cuellar-Garcia C., Blanco L., Sierra J., Nomdedeu J., Moreno C. (2020) Gene expression workflow to analyze residual leukemic cells in Chronic Lymphocytic Leukemia. INT J LAB HEMATOL, (), -.

IF: 2,8770

Moreno C. (2020) Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. HEMATOL-AM SOC HEMAT, 20 (1), 33-40.

IF: 3,0610

Novelli S., Martin A., Sanchez J.J., Espeso M., Mozos A., Briones J. (2020) Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units. EUR J DERMATOL, 30 (4), 397-403.

IF: 3,3280

Orti G., Palacio-Garcia C., Garcia-Cadenas I., Sanchez-Ortega I., Jimenez M.J., Azqueta C., Villacampa G., Ferra C., Parody R., Martino R., Bosch F., Querol S., Valcarcel D. (2020) Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. BIOL BLOOD MARROW TR, (), -.

IF: 5,7420

Pallarès V, Unzueta U, Falgàs A, Sánchez-García L, Serna N, Gallardo A, Morris GA, Alba-Castellón L, Álamo P, Sierra J, Villaverde A, Vázquez E, Casanova I, Mangues R. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. (2020) J HEMATOL ONCOL. Apr 15;13(1):36. doi: 10.1186/s13045-020-00863-9. PMID: 32295630.

IF: 17,3880

Penack O., Peczynski C., van der Werf S., Finke J., Ganser A., Schoemans H., Pavlu J., Niittyvuopio R., Schroyens W., Kaynar L., Blau I.W., van der Velden W., Sierra J., Cortelezzi A., Wulf G., Turlure P., Rovira M., Ozkurt Z., Pascual-Cascon M.J., Moreira M.C., Clausen J., Greinix H., Duarte R.F., Basak G.W. (2020) Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation – a prospective, non-interventional study of the EBMT Transplant Complication Working Party. HAEMATOLOGICA, 105 (7), 1977-1983.

IF: 9,9410

Penack O., Peczynski C., van der Werf S., Finke J., Ganser A., Schoemans H., Pavlu J., Niittyvuopio R., Schroyens W., Kaynar L., Blau I.W., van der Velden W.J.F.M., Sierra J., Cortelezzi A., Wulf G., Turlure P., Rovira M., Ozkurt Z., Pascual-Cascon M.J., Moreira M.C., Clausen J., Greinix H., Duarte R.F., Basak G.W. (2020) Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT – A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. FRONT IMMUNOL, 11 (), -.

IF: 7,5610

Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez- Catalan I, Coll R, De La Fuente I, Luna A, Merchán B, Chinea A, de Miguel D, Serrano A, Pérez C, Diaz C, Lopez JL, Saez AJ, Bailen R, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies (2020) EXP HEMATOL ONCOL. Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. PMID: 32864192.

IF: 5,1330

Ribera J.-M., Garcia O., Chapchap E.C., Gil C., Gonzalez-Campos J., Barba P., Amigo M.-L., Moreno M.-J., Lavilla E., Alonso N., Bergua J.-M., Tormo M., Ribera J., Sierra M., Martinez-Carballeira D., Mercadal S., Hernandez-Rivas J.-M., Vall-llovera F., Genesca E., Cladera A., Novo A., Abella E., Garcia-Cadenas I., Monteserin C., Bermudez A., Piernas S., Montesinos P., Lopez J.-L., Garcia-Guinon A., Serrano A., Martinez M.-P., Olivares M., Lopez A., Serrano J. (2020) Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. CL LYMPH MYELOM LEUK, 20 (8), e513-e522.

IF: 3,2310

Ribera J.-M., Morgades M., Montesinos P., Tormo M., Martinez-Carballeira D., Gonzalez-Campos J., Gil C., Barba P., Garcia-Boyero R., Coll R., Pedreno M., Ribera J., Mercadal S., Vives S., Novo A., Genesca E., Hernandez-Rivas J.-M., Bergua J., Amigo M.-L., Vall-Llovera F., Martinez-Sanchez P., Calbacho M., Garcia-Cadenas I., Garcia-Guinon A., Sanchez-Sanchez M.-J., Cervera M., Feliu E., Orfao A. (2020) A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. CANCER MED-US, 9 (7), 2317-2329.

IF: 4,4520

Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, García Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, et al. Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia (2020) BLOOD Nov 4:blood.2020007311. doi: 10.1182/blood.2020007311. PMID: 33150388.

IF: 22,1130

Schmidt-Hieber M., Engelhard D., Ullmann A., Ljungman P., Maertens J., Martino R., Rovira M., Shaw P.J., Robin C., Faraci M., Byrne J., Schafer-Eckart K., Einsele H., Faber E., Rigacci L., Saccardi R., Balaguer-Rosello A., Isaksson C., Christopeit M., Tridello G., Wang J., Knelange N., Mikulska M., Cesaro S., Styczynski J. (2020) Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. J NEUROL, 267 (2), 430-439.

IF: 4,8490

Sheth V., Volt F., Sanz J., Clement L., Cornelissen J., Blaise D., Sierra J., Michallet M., Saccardi R., Rocha V., Gluckman E., Chabannon C., Ruggeri A. (2020) Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers—On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. BIOL BLOOD MARROW TR, 26 (11), 2098-2104.

IF: 5,7420

Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Pérez-Encinas M, Coll R, Martí-Tutusaus JM, Brunet S, Sierra J, Ángel Sanz M, Montesinos P, Ribera JM, Vives S; PETHEMA, CETLAM cooperative groups. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols (2020) EUR J HAEMATOL Aug;105(2):138-147. doi: 10.1111/ejh.13417. PMID: 32243655.

IF: 2,9970

Snowden J.A., Saccardi R., Orchard K., Ljungman P., Duarte R.F., Labopin M., McGrath E., Brook N., de Elvira C.R., Gordon D., Poirel H.A., Ayuk F., Beguin Y., Bonifazi F., Gratwohl A., Milpied N., Moore J., Passweg J., Rizzo J.D., Spellman S.R., Sierra J., Solano C., Sanchez-Guijo F., Worel N., Gusi A., Adams G., Balan T., Baldomero H., Macq G., Marry E., Mesnil F., Oldani E., Pearce R., Perry J., Raus N., Schanz U., Tran S., Wilcox L., Basak G., Chabannon C., Corbacioglu S., Dolstra H., Kuball J., Mohty M., Lankester A., Montoto S., Nagler A., Styczinski J., Yakoub-Agha I., de la Tour R.P., Kroeger N., Brand R., de Wreede L.C., van Zwet E., Putter H. (2020) Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). BONE MARROW TRANSPL, 55 (4), 681-694.

IF: 5,4830

Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, García-Álvarez F, Gil C, Brunet S, Bergua J, González-Campos J, Ribera JM, Tormo M, González M, Fernández I, Benavente C, González-Sanmiguel JD, Esteve J, Pérez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanz MA, Montesinos P; PETHEMA, HOVON, PALG, GATLA cooperative groups. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols (2020) EUR J HAEMATOL Mar;104(3):162-169. doi: 10.1111/ejh.13346. PMID: 31724208.

IF: 2,9970

Solano C., Vazquez L., Gimenez E., de la Camara R., Albert E., Rovira M., Espigado I., Calvo C.M., Lopez-Jimenez J., Suarez-Lledo M., Chinea A., Esquirol A., Perez A., Bermudez A., Saldana R., Heras I., Gonzalez-Huerta A.J., Torrado T., Batlle M., Jimenez S., Vallejo C., Barba P., Cuesta M.A., Pinana J.L., Navarro D., Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment (2020) BONE MARROW TRANSPL.

IF: 5,4830

Sureda A., Chabannon C., Masszi T., Pohlreich D., Scheid C., Thieblemont C., Wahlin B.E., Sakellari I., Russell N., Janikova A., Dabrowska-Iwanicka A., Touzeau C., Esquirol A., Jantunen E., van der Werf S., Bosman P., Boumendil A., Liu Q., Celanovic M., Montoto S., Dreger P. (2020) Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. BONE MARROW TRANSPL, 55 (3), 613-622.

IF: 5,4830

Voso M.T., Larson R.A., Jones D., Marcucci G., Prior T., Krauter J., Heuser M., Lavorgna S., Nomdedeu J., Geyer S.M., Walker A., Wei A.H., Sierra J., Sanz M.A., Brandwein J.M., de Witte T.M., Jansen J.H., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Schlenk R.F., Ganser A., Amadori S., Cheng Y., Chen Y., Pallaud C., Du L., Piciocchi A., Ehninger G., Byrd J., Thiede C., Dohner K., Stone R.M., Dohner H., Bloomfield C.D., Lo-Coco F. (2020) Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial. BLOOD ADV, 4 (19), 4945-4954.

IF: 6,6860

Zhou Z., Nath R., Cerny J., Wang H.-L., Zhang M.-J., Abdel-Azim H., Agrawal V., Ahmed G., Al-Homsi A.S., Aljurf M., Alkhateeb H.B., Assal A., Bacher U., Bajel A., Bashir Q., Battiwalla M., Bhatt V.R., Byrne M., Cahn J.-Y., Cairo M., Choe H., Copelan E., Cutler C., Damlaj M.B., Defilipp Z., Lima M.D., Diaz M.A., Farhadfar N., Foran J., Freytes C.E.O., Gerds A.T., Gergis U., Grunwald M.R., Gul Z., Hamadani M., Hashmi S., Hertzberg M., Hildebrandt G.C., Hossain N., Inamoto Y., Isola L., Jain T., Kamble R.T., Khan M.W., Kharfan-Dabaja M.A., Kebriaei P., Kekre N., Khera N., Lazarus H.M., Liesveld J.L., Litzow M., Liu H., Marks D.I., Martino R., Mathews V., Mishra A., Murthy H.S., Nagler A., Nakamura R., Nathan S., Nishihori T., Olin R., Olsson R.F., Palmisiano N., Patel S.S., Patnaik M.M., Pawarode A., Perales M.-A., Politikos I., Popat U., Rizzieri D., Sandmaier B.M., Savani B.N., Seo S., Shah N.N., Uy G.L., Arcel D.V.A., Verdonck L.F., Waller E.K., Wang Y., Weisdorf D., Wirk B., Wong E., Yared J.A., Saber W. (2020) Reduced intensity conditioning for acute myeloid leukemia using melphalan-vs busulfan-based regimens: A CIBMTR report. BLOOD ADV, 4 (13), 3180-3190.

IF: 6,6860